Clinical Trials on HIV-1 Infection in Adults in New Zealand

Total 2111 results

Nina Bhardwaj
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaborators

Completed

Enhancement by Poly-ICLC During HIV-1 Infection (Poly-ICLC)

HIV-1 Infected Adults With Chronic HIV-1 Infection

United States
CytoDyn, Inc.

Completed

Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection

HIV Infections | HIV -1 Infection

United States
Rockefeller University

Completed

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

HIV-1 Infection

United States
Australian and New Zealand Intensive Care Research...
Intensive Care Foundation, Australia

Completed

TEAM: Trial of Early Activity and Mobilization (TEAM)

Critically Ill Adults Ventilated >24 Hours in Intensive Care

Australia, New Zealand
Rockefeller University

Completed

DCVax Plus Poly ICLC in Healthy Volunteers

HIV Infection | Healthy Volunteers | HIV-1 Infection

United States
Gen-Probe, Incorporated

Completed

Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay

HIV-1 Infection

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

A Study of the Safety and Antiretroviral Activity of 3BNC117

HIV-1 Infection

United States
Kirby Institute

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients (HSCT-HIV)

HIV-1 Infection

Australia
David Ho
Bill and Melinda Gates Foundation; International AIDS Vaccine Initiative; The...

Completed

10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults

HIV-1-infection

United States
International Partnership for Microbicides, Inc.

Completed

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

HIV-1 Infections

United States
Frontier Biotechnologies Inc.

Recruiting

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects (ABL)

HIV-1-infection

United States
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (BRAAVE 2020)

HIV-1 Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

HIV-1 Infection

Spain, United States, France, Italy, Germany, Canada, United Kingdom, Belgium, Puerto Rico, Australia
Tobira Therapeutics, Inc.

Completed

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women

HIV-1 Infection

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
ST Pharm Co., Ltd.

Recruiting

A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection

HIV-1-infection

United States
CytoDyn, Inc.

Active, not recruiting

PRO 140 in Treatment-Experienced HIV-1 Subjects

HIV-1-infection

United States
Montefiore Medical Center
Centers for Disease Control and Prevention

Completed

Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV

HIV-1-infection | Pre-exposure Prophylaxis

United States
Gilead Sciences

Completed

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

HIV-1-infection

United States, Puerto Rico, France, Germany, Austria, Canada
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

HIV-1 Infection

United States
Gilead Sciences

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

HIV-1-infection

United States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

HIV-1 Infection

United States, Puerto Rico
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral Infection

United States, New Zealand
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Spain, United States, Italy, Germany, United Kingdom, France, Australia, Puerto Rico, Canada, Belgium, Dominican Republic
International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
Holdsworth House Medical Practice

Completed

Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months (CVD)

Cardiovascular Disease | HIV-1 Infection

Australia
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Exegi Pharma...

Completed

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART

HIV-1 Infection

United States, Peru, Puerto Rico, Brazil, Botswana, Kenya, South Africa, Thailand
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, France, Germany, United Kingdom, Italy, Canada, Australia, Belgium, Puerto Rico, Dominican Republic
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)

HIV-1 Infection

United States
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

HIV-1 Infection

Spain, United Kingdom, Sweden, Germany, United States, France, Belgium, Ireland, Italy, Denmark, Puerto Rico, Canada
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

HIV-1 Infection

United States, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Bristol-Myers Squibb

Terminated

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

HIV-1 Infection

Thailand, United States, Australia, Canada, Spain, Colombia, South Africa, Hungary, France, Peru, Argentina, Chile, Mexico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

HIV-1 Infection

United States
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) (TRAFIC)

HIV-1 Infection

United States, Puerto Rico
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

HIV-1 Infection

United States, Puerto Rico
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

HIV-1 Infection

United States, United Kingdom, Canada, France, Italy, Puerto Rico, Belgium
TaiMed Biologics Inc.
Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research Center

Completed

Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers (TMB-108)

Prevention of Infection With HIV-1

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

France, Spain, Germany, United Kingdom, United States, Puerto Rico, Belgium, Canada, Italy, Dominican Republic
Gilead Sciences

Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

HIV-1 Infection

Spain, United States, United Kingdom, Switzerland, Germany, Canada, France, Belgium, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV-1 Infection

Canada, United States, Puerto Rico, Spain, United Kingdom, France, Portugal, Netherlands, Belgium, Italy, Australia, Austria, Germany, Switzerland
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir

HIV-1 Infection

United States
Gilead Sciences

Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

HIV-1 Infection

Russian Federation, United States, Thailand, Uganda, Puerto Rico, Dominican Republic
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Biomarkers to Predict Time to Plasma HIV RNA Rebound

HIV-1 Infection

United States, Puerto Rico, Thailand
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

HIV-1 Infection

United States, Puerto Rico

Clinical Trials on HIV-1 Infection in Adults in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations